BioLineRx Ltd
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. Show More...
-
Website https://www.biolinerx.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 5.25 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD 2.54 -16.16 -18.07 -11.4 -5.1 -4.2 -4.2 -4.05 -3.15 -2.55 -2.4 Dividends USD Payout Ratio % * Shares Mil 1.0 1.0 1.0 1.0 2.0 3.0 4.0 6.0 7.0 10.0 10.0 Book Value Per Share * USD 31.99 12.22 8.75 10.3 13.87 10.15 8.43 5.3 3.43 1.65 Free Cash Flow Per Share * USD -11.53 -17.97 -16.22 -7.64 -5.5 -3.79 -4.23 -3.65 -3.61 Return on Assets % -44.95 -76.11 -79.73 -36.26 -32.93 -35.11 -48.75 -39.19 -46.35 -45.2 Financial Leverage (Average) 1.3 1.62 1.71 1.14 1.08 1.11 1.15 1.36 1.6 1.65 Return on Equity % -58.52 -108.87 -132.38 -46.84 -36.28 -38.34 -55.4 -48.75 -68.13 -69.72 Return on Invested Capital % -65.61 -120.94 -137.83 -61.83 -36.99 -39.1 -56.85 -45.86 -51.91 -52.38 Interest Coverage 127.1 -13.76 -785.29 -852.31 -565.0 -959.0 -12.73 -13.25 Current Ratio 4.02 3.45 6.26 12.1 15.34 9.86 7.49 4.74 2.36 1.88 Quick Ratio 3.99 3.42 6.17 12.02 15.27 9.79 7.45 4.66 2.35 1.86 Debt/Equity 0.010 0.010 0.19 0.23 0.24